JETO HomeIssue Contents

Long-term benefit of intra-arterial bevacizumab for recurrent glioblastoma
Rachel A. Alter, Timothy G. White, Andrew A. Fanous, Shamik Chakraborty, Christopher G. Filippi, David J. Pisapia, Apostolos John Tsiouris and John A. Boockvar

Standard treatment for recurrent GBM is not yet established. We present a case demonstrating the benefit of intra-arterial (IA) bevacizumab with blood brain barrier disruption (BBBD) for the treatment of recurrent GBM. A 31 year-old man diagnosed with GBM, following primary resection, received temozolomide. After a second resection, he received one dose of IA bevacizumab with BBBD using mannitol, preventing regrowth for 2.5 years. Following tumor regrowth, the patient received another dose of IA bevacizumab with BBBD, which has prevented regrowth for another year.

Keywords: Blood Brain Barrier Disruption, Intra-arterial, Bevacizumab, Glioblastoma

Full Text (IP)